AI
HRTX icon

Atom Investors’s Heron Therapeutics HRTX Stock Holding History

Atom Investors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,178
Closed -$62.6K – 740
2025
Q4 		$62.6K Buy
+48,178
New +$59.5K 0.01% 542
2021
Q1 		– Sell
-25,551
Closed -$541K – 327
2020
Q4 		$541K Buy
25,551
+10,951
+75% +$190K 0.05% 237
2020
Q3 		$216K Buy
+14,600
New +$228K 0.02% 342
2019
Q4 		– Sell
-30,319
Closed -$561K – 265
2019
Q3 		$561K Buy
+30,319
New +$558K 0.04% 214
2019
Q1 		– Sell
-60,074
Closed -$1.56M – 604
2018
Q4 		$1.56M Buy
+60,074
New +$1.65M 0.15% 157

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Atom Investors's HRTX Position: Q1 2026 in Review

Atom Investors sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 48,178 shares — an estimated $62.6K sold.

Atom Investors first reported a position in HRTX in Q4 2018 and held it in 5 quarters. The position peaked at $1.56M in Q4 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Atom Investors reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Atom Investors sold 48,178 Heron Therapeutics shares in Q1 2026, an estimated $62.6K.
  • Atom Investors first reported a position in Heron Therapeutics in Q4 2018 and held it in 5 quarters.
  • Atom Investors's Heron Therapeutics position peaked at $1.56M in Q4 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.